The startup develops a drug discovery platform that integrates artificial intelligence with a wet-lab validation system to identify new mitophagy-activating drug candidates for Alzheimer's disease. By investigating the molecular mechanisms of aging and age-related diseases, the company aims to enhance both lifespan and health span for patients.
Funding
Funding not disclosed
Founders
Product
Problem
Alzheimer's disease and other age-related neurodegenerative conditions pose a significant and growing threat to global health, with limited effective treatments available. A key factor in these diseases is the accumulation of damaged cellular components due to the decline of essential cellular processes such as mitophagy. Current drug discovery methods often lack the ability to efficiently identify compounds that can restore or enhance these critical cellular functions.
Solution
The company is developing a drug discovery platform that leverages artificial intelligence (AI) and wet-lab validation to identify novel drug candidates capable of activating mitophagy for the treatment of Alzheimer's disease. The platform integrates AI-driven analysis of molecular mechanisms related to aging and age-related diseases with experimental models, including C. elegans, Drosophila melanogaster, mice, iPSC-differentiated neurons and glial cells, and human postmortem brain tissues, to validate drug candidates. By focusing on enhancing mitophagy, the platform aims to remove accumulated toxic proteins, reduce neuroinflammation, and improve overall neuronal health. The platform seeks to develop interventions that can improve both lifespan and healthspan by targeting the fundamental molecular mechanisms of aging.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing treatments for Alzheimer's disease and other age-related neurodegenerative disorders.
Features
- AI-driven drug discovery platform for identifying mitophagy-activating compounds
- Utilizes a cross-species experimental platform including C. elegans, Drosophila melanogaster, mice, iPSC-differentiated neurons and glial cells, and human postmortem brain tissues
- Focuses on molecular mechanisms of aging and age-related diseases
- Aims to enhance lifespan and healthspan through targeted interventions
- Integrates wet-lab validation to confirm the efficacy of AI-identified drug candidates